Form 4: Entrada Therapeutics' Chief Scientific Officer Sells Shares Under 10b5-1 Trading Plan

Natarajan Sethuraman, Chief Scientific Officer of Entrada Therapeutics, sold shares of common stock over three days in May under a pre-arranged 10b5-1 trading plan.

Summary

• Natarajan Sethuraman, the Chief Scientific Officer of Entrada Therapeutics, sold shares of the company's common stock.
• The sales occurred on May 16, 17, and 20, 2024.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 14, 2023.
• On May 16, 1,000 shares were sold at $15 per share.
• On May 17, 8,305 shares were sold at a weighted average price of $15.1416.
• On May 20, 9,675 shares were sold at a weighted average price of $15.188, with prices ranging from $15.00 to $15.34.
• Following these transactions, Sethuraman directly owns 190,052 shares of Entrada Therapeutics' common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a routine disclosure of insider selling under a pre-arranged plan, which doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Insider selling can be interpreted in various ways by the market. While a 10b5-1 plan suggests pre-arranged sales, investors often scrutinize the timing and volume of such transactions for insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• Shareholders may react to the news of insider selling, although the existence of a 10b5-1 plan may mitigate concerns.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal, as this is a routine transaction.

Key Dates